Cancer Research and Treatment

Original Article

Hepatic Resection Provides Survival Benefit for Selected Intermediate-Stage (BCLC-B) Hepatocellular Carcinoma Patients: Zhang Zhaohui, Shen Shunli, Chen Bin, Li Shaoqiang, Hua Yunpeng, Kuang Ming, Liang Lijian, Peng Bao Gang; Cancer Res Treat. 2019;51(1):65-72. Published online February 26, 2018; DOI: https://doi.org/10.4143/crt.2018.038

Purpose
The intermediate stage of hepatocellular carcinoma (HCC) (Barcelona Clinic Liver Cancer [BCLC] B) comprises a highly heterogeneous population, and the treatment strategy is still controversial. Because of the heterogeneity, a subclassification of intermediate-stage HCCs was put forward by Bolondi according to the ‘beyond Milan and within up-to-7’ criteria and Child-Pugh score. In this study, we aim to analyze the prognosis of BCLC-B stage HCC patients who received hepatic resection according to the Bolondi’s subclassification.
Materials and Methods
One thousand and one hundred three patients diagnosedwith HCC and treatedwith hepatic resectionwere enrolled in our hospital between 2006 and 2012. According to Bolondi’s subclassification, the BCLC-B patients were divided into four groups. Recurrence-free survival (RFS) and overall survival (OS) were analyzed.
Results
According to Bolondi’s subclassification, the BCLC-B patients were divided into four groups: B1 (n=41, 18.7%), B2 (n=160, 73.1%), B3 (n=11, 5.0%), and B4 (n=7, 3.2%). Significant difference was observed between B1 and other groups (B1 vs. B2, p=0.022; B1 vs. B3, p < 0.001; B1 vs. B4, p < 0.001), but no difference for B2 vs. B4 (p=0.542) and B3 vs. B4 (p=0.542). In addition, no significant differences were observed between BCLC-A and BCLC-B1 group for both RFS (p=0.087) and OS (p=0.643). In multivariate analysis, BCLC-B subclassification was not a risk factor for both OS (p=0.263) and RFS (p=0.892).
Conclusion
In our study, HCC patients at B1 stagewere benefited from hepatic resection and had similar survival to BCLC-A stage patients. Our study provided rationality of hepatic resection for selected BCLC-B stage HCC patients instead of routine transarterial chemoembolization.

Citations

Citations to this article as recorded by

Overexpression of tousled-like kinase 2 predicts poor prognosis in HBV-related hepatocellular carcinoma patients after radical resection
Bang Liu, Ling-Ling Lu, Li Yu, Xuan Mei, Jia Liu, Jiao-Long Zheng, Xiao-Ling Zhou, Hai-Yan Lin, Xiu-Ling Zhu, Dong-Liang Li
Frontiers in Genetics.2024;[Epub] CrossRef
Prognostic significance of early and multiple recurrences after curative resection for hepatocellular carcinoma
Akihiro Tanemura, Daisuke Noguchi, Toru Shinkai, Takahiro Ito, Aoi Hayasaki, Kazuyuki Gyoten, Takehiro Fujii, Yusuke Iizawa, Yasuhiro Murata, Naohisa Kuriyama, Masashi Kishiwada, Shugo Mizuno
BMC Surgery.2024;[Epub] CrossRef
TAC score better predicts survival than the BCLC following resection of hepatocellular carcinoma
Henrique A. Lima, Yutaka Endo, Zorays Moazzam, Laura Alaimo, Chanza Shaikh, Muhammad M. Munir, Vivian Resende, Alfredo Guglielmi, Hugo P. Marques, François Cauchy, Vincent Lam, George A. Poultsides, Irinel Popescu, Sorin Alexandrescu, Guillaume Martel, It
Journal of Surgical Oncology.2023; 127(3): 374. CrossRef
Multiplication of tumor maximum diameter and number as a new surgical indicator for Barcelona Clinic Liver Cancer intermediate‐stage hepatocellular carcinoma
Yuji Morine, Yu Saito, Shinichiro Yamada, Hiroki Teraoku, Yuhei Waki, Takayuki Noma, Tetsuya Ikemoto, Mitsuo Shimada
Hepatology Research.2023; 53(6): 531. CrossRef
Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in Canada
Jason K. Wong, Howard J. Lim, Vincent C. Tam, Kelly W. Burak, Laura A. Dawson, Prosanto Chaudhury, Robert J. Abraham, Brandon M. Meyers, Gonzalo Sapisochin, David Valenti, Setareh Samimi, Ravi Ramjeesingh, Amol Mujoomdar, Ilidio Martins, Elijah Dixon, Maj
Cancer Treatment Reviews.2023; 115: 102526. CrossRef
Advances in post-operative prognostic models for hepatocellular carcinoma
Ziqin He, Xiaomin She, Ziyu Liu, Xing Gao, Lu Lu, Julu Huang, Cheng Lu, Yan Lin, Rong Liang, Jiazhou Ye
Journal of Zhejiang University-SCIENCE B.2023; 24(3): 191. CrossRef
Preoperative alpha fetoprotein, total bilirubin, fibrinogen, albumin, and lymphocytes predict postoperative survival in hepatocellular carcinoma
Jia Xu, Shu An, Ying Lu, Laisheng Li, Zhi‐Qi Wu, Hua‐Guo Xu
Cancer Medicine.2023; 12(12): 13319. CrossRef
Liver resection versus transarterial chemoembolisation for the treatment of intermediate hepatocellular carcinoma: a systematic review and meta-analysis
Aleksandar Bogdanovic, Jelena Djokic Kovac, Predrag Zdujic, Uros Djindjic, Vladimir Dugalic
International Journal of Surgery.2023; 109(5): 1439. CrossRef
Surgical resection versus transarterial chemoembolization for patients with hepatocellular carcinoma beyond Milan criteria: prognostic role of tumor burden score
Shu-Yein Ho, Po-Hong Liu, Chia-Yang Hsu, Yi-Hsiang Huang, Hao-Jan Lei, Jia-I Liao, Chien-Wei Su, Ming-Chih Hou, Teh-Ia Huo
Scientific Reports.2023;[Epub] CrossRef
Clinical outcome of surgical resection for multifocal T2-T3 hepatocellular carcinoma up to 3 nodules: a comparative analysis with a single nodule
Sehyeon Yu, Hye-Sung Jo, Young-Dong Yu, Yoo jin Choi, Dong-Sik Kim
Journal of Liver Cancer.2023; 23(2): 377. CrossRef
Pretreatment Non-Invasive Biomarkers as Predictors to Estimate Portal Vein Tumor Thrombosis (PVTT) Risk and Long-Term Survival in HBV-Related Hepatocellular Carcinoma Patients Without PVTT
Bang Liu, Jia Liu, Xuan Mei, Zhi-Qiang Zhang, Jian Fang, Li-Li Zhou, Jiao-Long Zheng, Hai-Yan Lin, Xiu-Ling Zhu, Dong-Liang Li
Journal of Hepatocellular Carcinoma.2023; Volume 10: 2367. CrossRef
Tumor Burden Score and Serum Alpha-fetoprotein Subclassify Intermediate-Stage Hepatocellular Carcinoma
Henrique A. Lima, Yutaka Endo, Laura Alaimo, Zorays Moazzam, Muhammad Musaab Munir, Chanza Shaikh, Vivian Resende, Alfredo Guglielmi, Hugo P. Marques, François Cauchy, Vincent Lam, George A. Poultsides, Irinel Popescu, Sorin Alexandrescu, Guillaume Martel
Journal of Gastrointestinal Surgery.2022; 26(12): 2512. CrossRef
Comparison of 10 noninvasive models for predicting overall survival in patients with intermediate-stage hepatocellular carcinoma
Wei-Fan Hsu, Kai-Chih Chang, Te-Hong Chen, Chien-Hung Lin, Ying-Chun Lin, Ming-Hung Tsai, Pei-Yu Chen, Hung-Wei Wang, Chia-Sheng Chu, Cheng-Yuan Peng
Medicine.2021; 100(33): e27000. CrossRef
Hepatic Resection Versus Transarterial Chemoembolization for Intermediate-Stage Hepatocellular Carcinoma: A Cohort Study
Linbin Lu, Peichan Zheng, Zhixian Wu, Xiong Chen
Frontiers in Oncology.2021;[Epub] CrossRef
Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort
Vincent L. Chen, Amit G. Singal, Elliot B. Tapper, Neehar D. Parikh
Liver International.2020; 40(4): 947. CrossRef
Complex treatment of hepatocellular carcinoma at early (BCLC-A) and intermediate (BCLC-B) stages
B. N. Kotiv, I. I. Dzidzava, S. A. Alent’yev, A. V. Smorodsky, K. I. Makhmudov, A. A. Apollonov, S. A. Soldatov, P. N. Zubarev
Annaly khirurgicheskoy gepatologii = Annals of HPB Surgery.2020; 25(2): 55. CrossRef
A simple and clinically applicable model to predict liver-related morbidity after hepatic resection for hepatocellular carcinoma
Jonggi Choi, So-Hyun Kim, Seungbong Han, Danbi Lee, Ju Hyun Shim, Young-Suk Lim, Han Chu Lee, Young-Hwa Chung, Yung Sang Lee, Sung-Gyu Lee, Ki-Hun Kim, Kang Mo Kim, Leonidas G Koniaris
PLOS ONE.2020; 15(11): e0241808. CrossRef
BCLC-B Subclassification and the Hong Kong Liver Cancer System in Intermediate Hepatocellular Carcinoma
Larisse Longo, Laura B. Rodrigues de Freitas, Deivid Santos, Ivana Grivicich, Mário R. Álvares-da-Silva
American Journal of Clinical Oncology.2019; 42(5): 466. CrossRef

8,691 View
371 Download
19 Web of Science
18 Crossref

First
Prev
Page of 1
Next
Last

Search